Cinclus Pharma Holding ABFRA:J8P +1.37%4 Current Ratio is 2.89 as of Mar. 2026, which is 57% below its 10-year median of 6.78. GuruFocus rates FRA:J8P with a GF Score™ of 4/100. The stock has 3 warning signs investors should review. Among 997 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks better than 66.2% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cinclus Pharma Holding AB's current ratio for the quarter that ended in Mar. 2026 was 2.89.
Cinclus Pharma Holding AB has a current ratio of 2.89. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cinclus Pharma Holding AB's Current Ratio or its related term are showing as below:
FRA:J8P'
s Current Ratio Range Over the Past 10 Years
Min: 0.34 Med: 6.78 Max: 14.93
Current: 2.89
During the past 5 years, Cinclus Pharma Holding AB's highest Current Ratio was 14.93. The lowest was 0.34. And the median was 6.78.
FRA:J8P's Current Ratio is ranked better than 66.2% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:J8P: 2.89
Cinclus Pharma Holding AB (FRA:J8P) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cinclus Pharma Holding AB Current Ratio Related Terms
Cinclus Pharma Holding AB Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cinclus Pharma Holding AB (FRA:J8P) has a Current Ratio of 2.89 as of Mar. 2026. This is 57% below median its historical median of 6.78. Over the past decade, Cinclus Pharma Holding AB's Current Ratio has ranged from 0.34 to 14.93. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #337 out of 997 companies in the Drug Manufacturers industry, placing it in the top 33.8%.
Is Cinclus Pharma Holding AB's Current Ratio too high?
Cinclus Pharma Holding AB's current Current Ratio of 2.89 is 57% below median its 10-year median of 6.78. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 14.93. The Drug Manufacturers industry median Current Ratio is 2.00. Cinclus Pharma Holding AB's value of 2.89 is 44.5% above this industry median. Based on the distribution chart, Cinclus Pharma Holding AB ranks #337 out of 997 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cinclus Pharma Holding AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #337 out of 997 companies for Current Ratio. This puts Cinclus Pharma Holding AB in the upper half of its industry. The industry median Current Ratio is 2.00. Cinclus Pharma Holding AB's value of 2.89 is 44.5% above this benchmark. Historically, Cinclus Pharma Holding AB's own Current Ratio has ranged from 0.34 to 14.93 over the past decade. While the company's 10-year median is 6.78 vs. the industry median of 2.00, Cinclus Pharma Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cinclus Pharma Holding AB's current Current Ratio of 2.89 is 44.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current Current Ratio is 2.89, which is 57% below median its own 10-year median of 6.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Current Ratio of 2.89. The current Current Ratio is 2.89, which is 57% below median its 10-year median of 6.78 and 44.5% above the Drug Manufacturers industry median of 2.00. Cinclus Pharma Holding AB's overall GF Score™ is 4/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Current Ratio is 2.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
4GF Score
Get the complete analysis for FRA:J8P
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
